Table 2.
Clinical cure and microbiological eradication rates in the microbiologically evaluable population of the ATTAIN studies using telavancin MIC values obtained using the rBMD method
| Total | MIC (µg/mL) | ||||
|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | ||
| Clinical cure, n/N (%; 95% CIc) | |||||
| S. aureus (all) | 153/195 (78; 72, 84) | – | 36/46 (78; 64, 89) | 103/134 (77; 69, 84) | 14/15 (93; 68, 100) |
| S. aureus (MSSA) | 62/75 (83; 72, 90) | – | 22/26 (85, 65, 96) | 39/48 (81; 67, 91) | 1/1 (100; 3, 100) |
| S. aureus (MRSA) | 91/120 (76; 67, 83) | – | 14/20 (70; 46, 88) | 64/86 (74; 64, 83) | 13/14 (93; 66, 100) |
| S. aureus vancomycin MIC ≥1 µg/mLa | 131/166 (79; 72, 85) | – | 26/31 (84; 66, 95) | 91/120 (76; 67, 83) | 14/15 (93; 68, 100) |
| Microbiological eradication, n/N (%; 95% CIc) | |||||
| S. aureus (all) | 152/195 (78; 71, 84) | – | 34/46 (74; 59, 86) | 104/134 (78; 70, 84) | 14/15 (93; 68, 100) |
| S. aureus (MSSA) | 62/75 (83; 72, 90) | – | 22/26 (85; 65, 96) | 39/48 (81; 67, 91) | 1/1 (100; 3, 100) |
| S. aureus (MRSA) | 90/120 (75; 66, 82) | – | 12/20 (60; 36, 81) | 65/86 (76; 65, 84) | 13/14 (93; 66, 100) |
| S. aureus vancomycin MIC ≥1 µg/mLb | 130/166 (78; 71, 84) | – | 24/31 (77; 59, 90) | 92/120 (77; 68, 84) | 14/15 (93; 68, 100) |
ATTAIN Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; CI confidence interval; MIC minimum inhibitory concentration; MRSA methicillin-resistant S. aureus; MSSA methicillin-susceptible S. aureus; rBMD revised broth microdilution; S. aureus Staphylococcus aureus
aThese values included 48/56 patients with MSSA and 83/110 patients with MRSA
bThese values included 48/56 patients with MSSA and 82/110 patients with MRSA
cClopper–Pearson (Exact) confidence interval [22]